Widespread shortages of EpiPen, an epinephrine autoinjector for the treatment of anaphylaxis, have been resolved. The Therapeutic Goods Administration (TGA) confirmed this week the supply had returned to normal following a worldwide shortage that lasted almost a year. Issues with overseas manufacturers of the Mylan product in April 2018 had international ramifications, forcing those with…

Read More